Discover up-to-date Insights on metastatic NSCLC based on real-world data from our DXRX Network
The landscape of non-small cell lung cancer (NSCLC) treatment is evolving rapidly. Recent advancements in therapeutic options have reshaped treatment pathways, particularly for metastatic NSCLC. Traditionally dominated by chemotherapy, the current treatment pathway increasingly emphasizes targeted therapies and immunotherapies, offering new hope for improved patient outcomes.
NSCLC constitutes a staggering 85% of all lung cancer cases. In the US, biomarker testing plays a pivotal role in tailoring treatments, by assessing genetic mutations and protein expressions, clinicians can select optimal therapies, emphasizing the critical importance of understanding the biomarker landscape in NSCLC. By leveraging the robust capabilities of our DXRX Data Repository, we provide unparalleled insights into this landscape.
Diaceutics’ mission is to ensure that every patient receives the right treatment at the right time to positively benefit their disease outcome. Utilizing multiple integrated pipelines of real-world data on our platform, DXRX - The Diagnostic Network®, we deliver a complete view of the patient journey. Our unique business rules enable detailed patient analysis through a Diagnostic Deductive Pathway (DDP®), providing a granular understanding of each patient's steps along the complex treatment pathway. These insights empower our customers to refine their drug commercialization strategies.
Our analysis tracks the use of these innovative therapies, as well as the rise in the use of specific biomarkers such as PD-L1, EGFR, BRAF, and ALK. The evolving trends in metastatic NSCLC treatment impact the patient journeys of thousands of individuals diagnosed with this challenging disease. Lung cancer remains the leading cause of cancer-related deaths worldwide, and the prognosis for metastatic NSCLC has historically been poor. However, the advent of new treatments is gradually improving these outcomes, offering renewed hope for patients and their families.
Discover More
Discover more in our metastatic NSCLC Data Fact Sheet. Dive into the data and uncover how Diaceutics’ insights can enhance your drug commercialization strategies and implementation.
